Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

zimmer biomet holdings inc. - ZBH

ZBH

Close Chg Chg %
110.23 0.76 0.69%

Closed Market

110.99

+0.76 (0.69%)

Volume: 2.03M

Last Updated:

Nov 25, 2024, 3:59 PM EDT

Trade Now

Company Overview: zimmer biomet holdings inc. - ZBH

ZBH Key Data

Open

$110.60

 Day Range

110.14 - 111.85

52 Week Range

101.47 - 133.85

 Market Cap

$21.94B

Shares Outstanding

199.07M

 Public Float

198.80M

Beta

1.03

 Rev. Per Employee

N/A

P/E Ratio

21.00

 EPS

$5.27

Yield

87.10%

 Dividend

$0.24

EX-DIVIDEND DATE

Sep 30, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.78M

  

ZBH Performance

1 Week
 
 0.67%
 
1 Month
 
 8.41%
 
3 Months
 
 -3.55%
 
1 Year
 
 -2.18%
 
5 Years
 
 -22.05%
 

ZBH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About zimmer biomet holdings inc. - ZBH

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

ZBH At a Glance

Zimmer Biomet Holdings, Inc.
345 East Main Street
Warsaw, Indiana 46580
Phone 1-574-373-3333 Revenue 7.39B
Industry Medical Specialties Net Income 1.02B
Sector Health Technology 2023 Sales Growth 6.546%
Fiscal Year-end 12 / 2024 Employees 18,000
View SEC Filings

ZBH Valuation

P/E Current 20.998
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 24.922
Price to Sales Ratio 3.451
Price to Book Ratio 2.005
Price to Cash Flow Ratio 16.136
Enterprise Value to EBITDA 13.301
Enterprise Value to Sales 4.207
Total Debt to Enterprise Value 0.193

ZBH Efficiency

Revenue/Employee 410,788.889
Income Per Employee 56,888.889
Receivables Turnover 5.126
Total Asset Turnover 0.347

ZBH Liquidity

Current Ratio 1.613
Quick Ratio 0.778
Cash Ratio 0.146

ZBH Profitability

Gross Margin 63.063
Operating Margin 18.758
Pretax Margin 14.434
Net Margin 13.849
Return on Assets 4.812
Return on Equity 8.359
Return on Total Capital 5.542
Return on Invested Capital 5.874

ZBH Capital Structure

Total Debt to Total Equity 48.037
Total Debt to Total Capital 32.449
Total Debt to Total Assets 27.889
Long-Term Debt to Equity 40.401
Long-Term Debt to Total Capital 27.292
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Zimmer Biomet Holdings Inc. - ZBH

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
7.02B 7.84B 6.94B 7.39B
Sales Growth
-12.00% +11.56% -11.44% +6.55%
Cost of Goods Sold (COGS) incl D&A
2.77B 2.96B 2.60B 2.73B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.03B 1.07B 926.40M 951.70M
Depreciation
435.10M 451.70M 399.60M 390.20M
Amortization of Intangibles
597.60M 615.70M 526.80M 561.50M
COGS Growth
-3.62% +6.66% -12.00% +5.00%
Gross Income
4.25B 4.88B 4.34B 4.66B
Gross Income Growth
-16.72% +14.74% -11.10% +7.47%
Gross Profit Margin
+60.55% +62.28% +62.52% +63.06%
2020 2021 2022 2023 5-year trend
SG&A Expense
3.39B 3.63B 3.10B 3.28B
Research & Development
372.00M 497.20M 406.00M 458.70M
Other SG&A
3.02B 3.13B 2.70B 2.82B
SGA Growth
-11.18% +7.03% -14.51% +5.62%
Other Operating Expense
- 50.90M 53.10M 33.80M
Unusual Expense
934.90M 585.00M 703.30M 201.70M
EBIT after Unusual Expense
(122.60M) 614.00M 499.90M 1.19B
Non Operating Income/Expense
59.60M 12.20M 67.70M 77.30M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
211.40M 207.80M 164.10M 195.30M
Interest Expense Growth
-7.73% -1.70% -21.03% +19.01%
Gross Interest Expense
211.40M 207.80M 164.10M 195.30M
Interest Capitalized
- - - -
-
Pretax Income
(274.40M) 418.40M 403.50M 1.07B
Pretax Income Growth
-130.29% +252.48% -3.56% +164.51%
Pretax Margin
-3.91% +5.34% +5.81% +14.43%
Income Tax
(137.00M) 16.30M 112.30M 42.20M
Income Tax - Current - Domestic
(91.50M) 42.60M 191.40M 20.00M
Income Tax - Current - Foreign
(57.50M) 123.40M (14.70M) 118.50M
Income Tax - Deferred - Domestic
(35.70M) (137.40M) (73.20M) (141.90M)
Income Tax - Deferred - Foreign
47.70M (12.30M) 8.80M 45.60M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(137.40M) 402.10M 291.20M 1.03B
Minority Interest Expense
1.50M 500.00K 1.00M 1.10M
Net Income
(138.90M) 401.60M 290.20M 1.02B
Net Income Growth
-112.27% +389.13% -27.74% +252.86%
Net Margin Growth
-1.98% +5.12% +4.18% +13.85%
Extraordinaries & Discontinued Operations
- - - (58.80M)
-
Discontinued Operations
- - - (58.80M)
-
Net Income After Extraordinaries
(138.90M) 401.60M 231.40M 1.02B
Preferred Dividends
- - - -
-
Net Income Available to Common
(138.90M) 401.60M 231.40M 1.02B
EPS (Basic)
-0.671 1.9252 1.104 4.9066
EPS (Basic) Growth
-112.16% +386.92% -42.66% +344.44%
Basic Shares Outstanding
207.00M 208.60M 209.60M 208.70M
EPS (Diluted)
-0.671 1.9088 1.1003 4.8832
EPS (Diluted) Growth
-112.26% +384.47% -42.36% +343.81%
Diluted Shares Outstanding
207.00M 210.40M 210.30M 209.70M
EBITDA
1.84B 2.27B 2.13B 2.34B
EBITDA Growth
-16.67% +22.84% -6.04% +9.82%
EBITDA Margin
+26.27% +28.92% +30.69% +31.63%

Snapshot

Average Recommendation HOLD Average Target Price 124.04
Number of Ratings 31 Current Quarters Estimate 2.30
FY Report Date 12 / 2024 Current Year's Estimate 7.992
Last Quarter’s Earnings 1.74 Median PE on CY Estimate N/A
Year Ago Earnings 7.55 Next Fiscal Year Estimate 8.59
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 28 19 29 29
Mean Estimate 2.30 2.06 7.99 8.59
High Estimates 2.35 2.16 8.08 8.83
Low Estimate 2.26 1.95 7.95 8.43
Coefficient of Variance 0.92 2.43 0.36 1.02

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 7
OVERWEIGHT 2 2 3
HOLD 19 19 18
UNDERWEIGHT 0 0 0
SELL 2 2 2
MEAN Hold Hold Hold

Insider Actions for Zimmer Biomet Holdings Inc. - ZBH

Date Name Shares Transaction Value
Jul 4, 2024 Wilfred van Zuilen Group Pres, EMEA 2,631 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 4, 2024 Wilfred van Zuilen Group Pres, EMEA 9,243 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $107.36 per share 992,328.48
Jul 4, 2024 Wilfred van Zuilen Group Pres, EMEA 9,800 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 3, 2024 Arthur Joseph Higgins Director 33,037 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Sreelakshmi Kolli Director 3,773 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Devdatt Kurdikar Director 127 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Louis A. Shapiro Director 847 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Syed A. Jafry Director 5,854 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Michael J. Farrell Director 14,586 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Robert A. Hagemann Director 28,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Maria Teresa Hilado Director 8,487 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Christopher B. Begley Director 20,147 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Paul Stellato VP, Controller & CAO 1,579 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 5, 2024 Paul Stellato VP, Controller & CAO 1,382 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $114.47 per share 158,197.54
Jun 5, 2024 Sang Yi Group President, Asia Pacific 5,322 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $114.69 per share 610,380.18
Jun 5, 2024 Paul Stellato VP, Controller & CAO 626 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Michael W. Michelson Director 8,550 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 15, 2024 Michael W. Michelson Director 12,240 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 15, 2024 Robert A. Hagemann Director 22,998 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 15, 2024 Arthur Joseph Higgins Director 23,453 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Zimmer Biomet Holdings Inc. in the News